[10/3/2025] Today, the U.S. Food and Drug Administration (FDA) is announcing a new pilot prioritization program for the review of abbreviated new drug applications (ANDAs) (ANDAs) that aims to spur and reward investment in U.S. drug manufacturing and research and development and strengthen the domestic pharmaceutical supply chain by providing faster reviews for generic companies who test and manufacture their products in the U.S.Continue reading
Author Archive: AZBio
Falloposcope cancer screening tool testing advances to next steps
Jennifer Barton, PhD, is spearheading an effort to diagnose ovarian cancer earlier and give high-risk patients a new option.Continue reading
AdvaMed Releases Technical Performance and Safety Bulletin on “Remote Device Operations: Common Challenges and Mitigation Strategies”
WASHINGTON, D.C. – AdvaMed, the Medtech Association, recently published a technical performance and safety bulletin titled, “Remote Device Operations: Common Challenges and Mitigation Strategies” to help health care providers, device manufacturers, and IT teams navigate the complex landscape of remotely managing medical devices.Continue reading
U of A celebrates new AI-powered MRI and BIO5 Brain & Body Imaging Center
The new systems represent a leap in non-invasive imaging. The machines, powered by artificial intelligence, open new possibilities for treating neurological diseases such as Alzheimer’s and Parkinson’s, as well as expanding the capabilities for imaging the heart, lungs and liver – even for patients with metallic implants.
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
- Voluntary agreement meets the President’s four requests while also protecting the U.S. ecosystem responsible for America’s leadership in delivering medical breakthroughs
- Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer’s ability to expand investment in U.S.-based innovation and return manufacturing to the U.S.
- Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology
- Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today
PhRMA Announces Major Actions as Part of Industry’s Commitment to American Patients and Workers
WASHINGTON, D.C. (September 29, 2025) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced three major actions as part of the biopharmaceutical industry’s commitment to American patients and workers.
PhRMA member companies are making historic investments in U.S.-based manufacturing and infrastructure, providing financial assistance to millions of insured and underinsured patients who have been failed by a broken health insurance system, and announcing a new website that will simplify access to manufacturer direct purchase and patient assistance resources. Continue reading
A new era in ASU X-ray science officially begins
First X-ray machine’s commissioning milestone marks start of research phase for one-of-a-kind labContinue reading
The Value of Managing Valley Fever for Arizona Stakeholders
Managing Valley fever starts with awareness. Since there’s no surefire way to avoid getting Valley fever in Arizona, knowledge is everyone’s best defense — but awareness needs a community effort. Continue reading
Governor Katie Hobbs Appoints Virginia “Ginny” Rountree to lead AHCCCS
Governor Katie Hobbs Appoints Virginia “Ginny” Rountree to lead AHCCCSContinue reading
Administration Announces a 100 Percent Potential Tariff on Branded or Patented Pharmaceuticals
President Trump posted the following on Truth Social on Thursday, September 25, 2025: “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America. “IS BUILDING” will be defined as, “breaking ground” and/or “under construction.” There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started. Thank you for your attention to this matter!” Source: https://truthsocial.com/@realDonaldTrump/115267512131958759Continue reading